VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug

Viking Therapeutics completed enrollment in the second Phase III obesity study for VK2735, a key clinical milestone that advances its position in the fast-growing weight‑loss market. The enrollment completion drove a positive share reaction and de-risks the development timeline, improving the company's prospects in a competitive therapeutic area.

Analysis

Viking Therapeutics completed enrollment in the second Phase III obesity study for VK2735, a key clinical milestone that advances its position in the fast-growing weight‑loss market. The enrollment completion drove a positive share reaction and de-risks the development timeline, improving the company's prospects in a competitive therapeutic area.